EQS-Ad-hoc: LR Health & Beauty SE / Key word(s): Change in Forecast/Quarter Results Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR) LR Health & Beauty SE: Publication of figures for the third quarter of 2024 and adjustment of the forecast for the 2024 financial year Ahlen, 26 November 2024 – In the third quarter of 2024 LR Health & Beauty SE (bond, ISIN NO0013149658) increased sales (revenue from goods sold) by 7.2% to EUR 69.4 million (Q3 2023: EUR 64.7 million). Accordingly, sales in the first nine months of 2024 totaled EUR 212.7 million (9M 2023: EUR 205.6 million). In the third quarter of 2024 EBITDA reported amounted to EUR 7.3 million (Q3 2023: EUR 7.1 million). For the first nine months of 2024 EBITDA reported thus totaled EUR 19.0 million (9M 2023: EUR 22.4 million). Based on the business results for the first nine months of 2024 and the realignment of the career plan for distributors in the third quarter of 2024, LR Health & Beauty SE is adjusting its forecast for sales and EBITDA reported for the full year 2024. LR Health & Beauty SE is increasing the sales guidance for the 2024 financial year and now expects sales to range in a corridor of EUR 288 million to EUR 292 million. Management originally assumed that sales (revenue from goods sold) would be at the previous year's level (2023: EUR 276.5 million). The company is also adjusting its earnings expectations for 2024 and revising its forecast for EBITDA reported to be in the range of EUR 26 million to EUR 29 million. Originally, management expected a slightly lower to stable EBITDA figure year-on-year (2023: EUR 31.4 million). The underlying reason is that the realignment of the career plan for partners in the third and fourth quarters of 2024 will lead to a significant increase in distributors, which will have a positive impact on sales development. At the same time, the result is burdened by refinancing costs incurred and, above all, by one-off, extraordinary effects in the low single-digit million euro range due to changes to the distributors' career plan. cometis AG End of Inside Information
26-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | LR Health & Beauty SE |
Kruppstr. 55 | |
59227 Ahlen | |
Germany | |
Phone: | +49 238270600 |
E-mail: | info@lrworld.com |
Internet: | www.lrworld.com |
ISIN: | NO0013149658 |
WKN: | A3H3FM |
Listed: | Regulated Unofficial Market in Frankfurt; Stockholm |
EQS News ID: | 2038593 |
End of Announcement | EQS News Service |
|
2038593 26-Nov-2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.